All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

CSL Seqirus receives Australian approval for neffy (adrenaline) nasal spray treating anaphylaxis in adults and children
Protein therapy, allergic reactions, epinephrine, anaphylaxis, nasal spray, emergency treatment - Read more

Encora Therapeutics receives FDA clearance for Encora X1 wearable neurostimulation device treating essential tremor
Medical device, neurological, neurostimulation, essential tremor, wearable technology - Read more

Amgen's Uplizna (inebilizumab) wins European Commission approval for generalized myasthenia gravis targeting CD19-positive B cells
Antibody, autoimmune, monoclonal antibody, generalized myasthenia gravis, CD19 target, B-cell depletion - Read more

THE GOOD
Business Development & Partnerships

Psyence BioMed, PsyLabs approve put option agreement for strategic psychedelic compound supply and manufacturing access
Manufacturing agreement, neurological, equity investment, licensing deal - Read more

Lupin, Spektus Pharma license agreement to commercialize novel antidepressant DeslaFlex in Canada
Licensing deal, neurological, drug delivery, commercialization - Read more

Zeon Corporation invests in Chemify to accelerate digital chemistry innovation and develop new materials
Strategic investment, digital chemistry, small molecule, automated synthesis, materials development - Read more

Gilead, Genhouse Bio partner on cancer drug GH31, $80M upfront, $1.45B milestones
Licensing deal, oncology, small molecule, milestone payments - Read more

PRESENTED BY FACET LIFE SCIENCES
Facet Life Sciences Makes Emerging Biotech Approvable

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

✅ More Good News ✅

THE GOOD
Clinical Trials

Eli Lilly's Retevmo (selpercatinib) shows Ph3 success in early-stage RET fusion-positive non-small cell lung cancer
Small molecule, cancer, kinase inhibitor, non-small cell lung cancer, RET fusion, adjuvant therapy - Read more

Novartis' Vanrafia (atrasentan) shows kidney function benefits in Ph3 trial, positioning for full FDA approval in immunoglobulin A nephropathy
Small molecule, kidney disease, endothelin receptor antagonist, IgA nephropathy, proteinuria - Read more

Genentech's Gazyva (obinutuzumab) meets Ph3 primary endpoint for primary membranous nephropathy treatment
Antibody, autoimmune, monoclonal antibody, primary membranous nephropathy, CD20 target - Read more

THE GOOD
Earnings & Finances

Vertex Pharmaceuticals and CRISPR Therapeutics project $500M combined revenue for Casgevy gene therapy by 2026
Gene therapy, rare disease, revenue impact, strategic - Read more

Moderna shares rise 5% despite FDA rejecting flu vaccine application over trial design issues
mRNA vaccine, infectious disease, regulatory, financial - Read more

THE GOOD
Fundraises

Medikra raises $25M IPO, botanical therapeutics for obesity and metabolic syndrome
Botanical therapeutics, obesity, metabolic syndrome, clinical-stage - Read more

BioRestorative raises $5M public offering, stem cell-based regenerative medicine therapies
Regenerative medicine, stem cell therapy, clinical-stage, biocosmeceuticals - Read more

Cencora closes $3.0 billion senior notes offering to repay OneOncology acquisition debt and corporate purposes
Oncology, financial, major transaction, debt refinancing - Read more

Nektar Therapeutics raises $460M public offering, clinical-stage immunotherapy medicine development
Immunotherapy, clinical-stage, biotechnology - Read more

Newron Pharmaceuticals raises €38M equity funding, advancing Phase III evenamide program
Neurological, schizophrenia, clinical-stage, small molecule - Read more

Immunic raises $400M private placement, oral therapies for neurologic, gastrointestinal diseases
Neurological, gastrointestinal, oral therapies, late-stage - Read more

AMPLY Discovery receives undisclosed strategic investment for AI-driven drug discovery platform
AI/ML platform, drug discovery, oncology, platform technology - Read more 

THE GOOD
Investments

Sanofi to expand India GCC with multi-hundred-million investment, doubling workforce to 4,500 employees
Operational, major transaction, workforce expansion - Read more

THE GOOD
Mergers & Acquisitions

Worldwide Clinical Trials completes acquisition of Catalyst Clinical Research to enhance oncology and FSP capabilities
Oncology, strategic, major transaction, operational - Read more

THE GOOD
Strategic Plans

Eli Lilly stockpiles $1.5B orforglipron inventory ahead of FDA approval while Novo expands Wegovy pill internationally
Small molecule, obesity, strategic, major transaction, operational - Read more

Moonwalk Biosciences pivots from epigenetic editing to siRNA obesity therapies under Feng Zhang's leadership
siRNA, obesity, strategic, operational - Read more [Paywall]

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA rejects Disc Medicine's bitopertin (GlyT1 inhibitor) accelerated approval for erythropoietic protoporphyria, requests Ph3 data
Small molecule, rare disease, GlyT1 inhibitor, erythropoietic protoporphyria - Read more

THE BAD
Earnings & Finances

Moderna R&D spend drops 31% to $3.1B in 2025 amid respiratory pipeline wind-down
mRNA vaccine, infectious disease, cost reduction, operational - Read more

THE BAD
Layoffs

Ultragenyx Pharmaceutical lays off 10% of workforce amid failed trials and FDA gene therapy delays
Gene therapy, rare disease, operational, cost reduction - Read more

Integra LifeSciences cuts 65 roles at Princeton site following MediHoney wound device recall
Medical device, wound care, operational, cost reduction - Read more

THE BAD
Politics & Policy

Jim O'Neill exits HHS Deputy Secretary and CDC interim head roles amid Trump administration reshuffle
Regulatory, operational, strategic, leadership - Read more

THE BAD
Regulatory

Biohaven CEO criticizes FDA red tape blocking rare disease treatments after SCA therapy rejection
Small molecule, rare disease, regulatory, operational - Read more

Trump administration seeks stakeholder input on 340B rebate pilot program through HRSA request for information
Drug discount program, regulatory, operational, financial - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here